For Investors

Presentations and Webinars

Webinars

Emyria receives further positive MDMA-analogue screening results 10 May 2022

EMD-RX5 Recruitment Begins 8 March 2022

ShareCafe Small Cap “Hidden Gems” Webinar 7 March 2022

Presentation | South-West Connect Event 27 October 2021

Video | Proactive Biosciences Webinar 28 September 2021

Investor Webinar | Drug Development Programs and Overview 24 August 2021

Investor Webinar | Emyria and Cann Group Partnership 9 April 2021

ASX Announcements

Stock Information

Emyria Limited (ASX:EMD ) is an Australian public company that commenced trading on the Australian Securities Exchange (ASX) on 12 February 2020, a data-backed, drug development company that elevates clinical care and delivers deeper clinical insights.

We see a global opportunity and believe that much of what we want to achieve today is already possible by bringing together the right talent and technology and staying caring, curious and courageous.